Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
1.
Clin Lab Haematol ; 25(1): 25-8, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12542438

ABSTRACT

Autohaemolysis testing can assist the evaluation of haemolytic anaemia, but involves a cumbersome assay that is difficult to perform accurately. Because this test persists in clinical practice without clear indications or guidelines, we retrospectively reviewed our experience with autohaemolysis testing for children with suspected congenital haemolytic anaemia. Over 12 years, autohaemolysis without glucose was elevated for 38 of 39 children with congenital spherocytosis, while glucose corrected or reduced autohaemolysis in 33 of these patients. Autohaemolysis was elevated only once among seven other cases (four with congenital nonspherocytic haemolytic anaemia and three normal siblings). In three cases of congenital spherocytosis with equivocal osmotic fragility, autohaemolysis was abnormal and corrected with glucose in two. In our experience, autohaemolysis testing was helpful diagnostically in only two of 54 cases, so has only limited utility as a routine test for children with suspected congenital haemolytic anaemia.


Subject(s)
Anemia, Hemolytic, Congenital/diagnosis , Hematologic Tests/instrumentation , Hemolysis/physiology , Adolescent , Automation , Blood Glucose , Child , Child, Preschool , Female , Humans , Infant , Male , Osmotic Fragility/physiology , Retrospective Studies
2.
Br J Radiol ; 75(890): 114-21, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11893634

ABSTRACT

The purpose of this study was to document the accuracy of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) with sodium iodide detectors in characterizing indeterminate lung nodules or masses and in identifying additional extra-lesional findings. 50 consecutive patients without a confident diagnosis of malignancy on CT underwent (18)FDG PET with and without attenuation correction. The diagnosis of malignancy was made using visual diagnostic criteria, and tumour-to-blood pool ratios were calculated. The final diagnosis was established by surgery, biopsy or long-term follow-up. Any additional findings made at PET were recorded and similarly verified. Using blinded visual diagnostic criteria for the differentiation of malignant from benign nodules, sodium iodide PET achieved a sensitivity of 91% (30 of 33 cases), a specificity of 88% (15 of 17 cases), a positive predictive value for malignancy of 94% (30 of 32 cases) and a negative predictive value of 83% (15 of 18 cases). False positives occurred with active tuberculosis and sarcoidosis. False negatives were a 3 cm bronchoalveolar carcinoma, a 1.3 cm sarcoma metastasis and a 1 cm carcinoma. Use of tumour-to-blood pool ratios did not improve performance. PET suggested the presence of nodal or distant metastases in 13 of 33 patients with a malignant pulmonary lesion. These PET findings were confirmed in 11 patients. These results indicate that sodium iodide PET is an accurate tool for the characterization of indeterminate pulmonary masses or nodules and simultaneously provides non-invasive staging information that can alter patient management in up to one-third of such patients. Performance of sodium iodide PET is comparable with reported results for PET scanners using other detector materials.


Subject(s)
Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Radiopharmaceuticals , Aged , Aged, 80 and over , Diagnosis, Differential , Diagnostic Errors , Female , Follow-Up Studies , Humans , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Neoplasm Staging , Predictive Value of Tests , Sodium Iodide , Tomography, Emission-Computed/methods
3.
Exp Hematol ; 29(12): 1403-9, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11750098

ABSTRACT

OBJECTIVE: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematological disorder with acquired PIG-A gene mutations and absent surface expression of proteins utilizing glycosylphosphatidylinositol (GPI) anchors. PNH often follows aplastic anemia, suggesting PIG-A mutant cells have relative dominance over normal hematopoietic cells. Somatic PIG-A mutations could arise after aplasia, or healthy persons could have rare PIG-A mutant cells that expand under selection pressure. METHODS: We developed an in vitro negative selection method to isolate GPI-deficient T lymphocytes using aerolysin, an Aeromonas toxin that binds GPI anchors and induces cell lysis. Peripheral blood mononuclear cells (PBMC) from normal adults and patients with PNH or other bone marrow failure syndromes were analyzed. RESULTS: From healthy adults, 166 T lymphocyte clones with deficient GPI-linked surface protein expression (CD55, CD59) were isolated. The mean mutant frequency (M(f)) of aerolysin-resistant clones was 17.8 +/- 13.8 per 10(6) PBMC, range 5.0-59.6 per 10(6) cells. Clones had a Class A complementation defect and distinct PIG-A mutations. Patients with PNH had elevated aerolysin-resistant M(f) values averaging 19 x 10(-2), a 10,000-fold difference. Two patients with Fanconi anemia and two others with mild aplastic anemia had M(f) values less than 15 x 10(-6), but two with recovering aplastic anemia had M(f) values of 20 x 10(-4), representing an intermediate value between normal persons and PNH patients. CONCLUSION: Identification of PIG-A mutant T lymphocytes in healthy adults suggests PNH could develop following intense negative selection of hematopoiesis, with clonal outgrowth of naturally occurring PIG-A mutant stem cells.


Subject(s)
Anemia, Aplastic/genetics , Bone Marrow Diseases/immunology , Hemoglobinuria, Paroxysmal/genetics , Membrane Proteins/genetics , Mutation , Myelodysplastic Syndromes/immunology , T-Lymphocytes/immunology , Adult , Antigens, CD/analysis , Bacterial Toxins/pharmacology , Bone Marrow Diseases/genetics , Cell Separation/methods , Clone Cells , DNA, Complementary/genetics , Genetic Complementation Test , Glycosylphosphatidylinositols/deficiency , Humans , Membrane Proteins/deficiency , Myelodysplastic Syndromes/genetics , Pore Forming Cytotoxic Proteins , Reference Values , T-Lymphocytes/cytology , T-Lymphocytes/drug effects
4.
J Pediatr ; 139(6): 790-6, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11743503

ABSTRACT

OBJECTIVE: Hydroxyurea improves hematologic values and decreases vaso-occlusive complications in adults and children with sickle cell anemia (SCA), but has not been tested in infants before the onset of chronic organ dysfunction. We conducted a collaborative pilot trial of hydroxyurea in infants with SCA to assess its (1) feasibility of administration, (2) toxicity, (3) hematologic effects, and (4) effect on spleen function. STUDY DESIGN: Patients with hemoglobin (Hb) SS or Sbeta(0) thalassemia (n = 28, median age 15 months) received hydroxyurea for 2 years at 20 mg/kg/day. Hydroxyurea was temporarily discontinued for predefined toxicity. RESULTS: Seven patients exited the study early: five for noncompliance or refusal to continue, one for mild stroke, and one for fatal splenic sequestration. The predominant toxicity was transient neutropenia, which was usually associated with a viral-like illness. After 2 years of treatment, mean Hb level = 8.8 g/dL and Hb F = 20.3%, both higher than predicted age-specific levels. Radionuclide splenic uptake was absent in 47% of patients at study completion, compared with predicted functional asplenia in 80% of the patients. CONCLUSIONS: Hydroxyurea therapy for infants with SCA is feasible and well tolerated, has hematologic efficacy, and may delay functional asplenia. The potential for hydroxyurea to preserve organ function in SCA should be further evaluated.


Subject(s)
Anemia, Sickle Cell/drug therapy , Antisickling Agents/therapeutic use , Hemoglobins/drug effects , Hydroxyurea/therapeutic use , Splenic Diseases/prevention & control , Age Factors , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/complications , Antisickling Agents/adverse effects , Antisickling Agents/toxicity , Blood Cell Count , Child, Preschool , Feasibility Studies , Female , Hematologic Diseases/blood , Hematologic Diseases/chemically induced , Hemoglobins/analysis , Humans , Hydroxyurea/adverse effects , Hydroxyurea/toxicity , Infant , Male , Pilot Projects , Splenic Diseases/blood , Splenic Diseases/etiology , Time Factors
5.
J Nucl Med ; 42(11): 1605-13, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11696628

ABSTRACT

UNLABELLED: After potentially curative therapy of non-small cell lung cancer (NSCLC), masses or symptoms suggestive of relapse are common but may be difficult to characterize. Early detection is important because salvage therapies are available for localized recurrence. This study evaluated whether (18)F-FDG PET is useful and predictive of outcome in this setting. METHODS: For 63 consecutive patients with suspected relapse >6 mo after definitive treatment of NSCLC, the apparent extent of disease on conventional restaging was compared with that on FDG PET. Patients with already confirmed systemic metastases were excluded unless locally aggressive treatment of these was being considered. Serial imaging and pathologic results were obtained during a median follow-up of 19 mo to validate diagnostic findings. Prognostic significance was tested using the Cox proportional hazards regression model. RESULTS: PET had positive findings in 41 of 42 patients with confirmed relapse (sensitivity, 98%). No disease was evident during a minimum follow-up of 12 mo in 14 of 15 patients with clinically suspected relapse but negative PET findings (negative predictive value, 93%). PET induced a major management change in 40 patients (63%), including 6 whose treatment was changed from curative to palliative, 3 whose treatment was changed from palliative to curative, and 9 for whom negative PET findings prevented active management. Both the presence (P = 0.012) and the extent (P < 0.0001) of relapse on PET were highly significant prognostic factors. There was also significant prognostic stratification based on the treatment delivered after the PET study (P = 0.011), but after adjustment for this treatment, PET status remained highly predictive of survival. CONCLUSION: PET better assesses the status of disease and stratifies prognosis than does conventional staging, affects patient management, and should be incorporated into paradigms for suspected recurrence of NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Neoplasm Recurrence, Local/diagnostic imaging , Radiopharmaceuticals , Aged , Carcinoma, Non-Small-Cell Lung/therapy , Female , Humans , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Radionuclide Imaging , Survival Analysis
6.
J Nucl Med ; 42(11): 1596-604, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11696627

ABSTRACT

UNLABELLED: Survival of lung cancer patients remains poor despite increasingly aggressive treatment. Conventional staging has well-described limitations. (18)F-FDG PET has been shown to stage lung cancer more accurately than does CT scanning, but the impact on patient treatment and outcome is poorly defined. This study evaluated this impact in routine clinical practice within a tertiary oncology facility. METHODS: For 153 consecutive patients with newly diagnosed non-small cell lung cancer, the treatment plan based on conventional staging methods was compared with the treatment plan based on incorporation of PET findings. Survival was analyzed using the Cox proportional hazards regression model. RESULTS: For broad groupings of stage, 10% of cases were downstaged and 33% upstaged by PET. When assessable, the PET stage was confirmed in 89% of patients. PET had a high impact on 54 patients (35%), including 34 whose therapy was changed from curative to palliative, 6 whose therapy was changed from palliative to curative, and 14 whose treatment modality was changed but not the treatment intent. For 39 patients (25%), a previously selected therapy was altered because of the PET findings. The Cox model indicated that the pre-PET stage was significantly associated with survival (P = 0.013) but that the post-PET stage provided much stronger prognostic stratification (P < 0.0001) and remained significant after adjustment for treatment delivered. CONCLUSION: Staging that incorporated PET provided a more accurate prognostic stratification than did staging based on conventional investigations. Further, the additional information provided by PET significantly and appropriately changed management in the majority of patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Radiopharmaceuticals , Aged , Carcinoma, Non-Small-Cell Lung/therapy , Female , Follow-Up Studies , Humans , Image Processing, Computer-Assisted , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Prospective Studies , Radionuclide Imaging , Survival Analysis
7.
Med J Aust ; 175(6): 303-7, 2001 Sep 17.
Article in English | MEDLINE | ID: mdl-11665943

ABSTRACT

OBJECTIVE: To document the usefulness of positron emission tomography (PET) in diagnosing lung masses where tissue diagnosis is not possible or is unhelpful. DESIGN: Cohort study (partly retrospective). SETTING: Departments of positron emission tomography and diagnostic imaging of a tertiary referral dedicated cancer hospital in Melbourne. PATIENTS: 40 of 60 consecutive patients referred for evaluation of an indeterminate lung nodule or mass, comprising 15 in whom biopsy was not possible and 25 in whom biopsy had either failed or did not confirm malignancy or a specific benign diagnosis. MAIN OUTCOME MEASURES: Accuracy of blinded reading of PET scans in determining whether the lung lesion is benign or malignant (final diagnosis established either through surgical biopsy or from long term clinical and imaging follow-up). RESULTS: PET yielded 23 true positives, 13 true negatives, 3 false positives (2 tuberculosis, 1 sarcoidosis) and 1 false negative (an adenocarcinoma), giving a sensitivity of 96%, a specificity of 81%, a negative predictive value of 93%, and a positive predictive value of 88% (for malignancy). CONCLUSIONS: For lung nodules where tissue diagnosis was not possible or was unhelpful, the negative predictive power of PET was sufficiently high to avoid open biopsy, and to follow such patients with serial surveillance. On the other hand, most lesions that were positive on PET were either malignant or required specific active management determined from histological characterisation. PET therefore contributed to improved patient management and has reduced the need for open thoracotomy.


Subject(s)
Lung Neoplasms/diagnostic imaging , Tomography, Emission-Computed/standards , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Cohort Studies , Diagnosis, Differential , Humans , Lung Neoplasms/pathology , Predictive Value of Tests , Prospective Studies , Radiography , Retrospective Studies , Sensitivity and Specificity
8.
J Pediatr Hematol Oncol ; 23(5): 306-8, 2001.
Article in English | MEDLINE | ID: mdl-11464988

ABSTRACT

PURPOSE: Hydroxyurea (HU) has laboratory and clinical efficacy in hemoglobin SS (HbSS) disease, but its benefits in hemoglobin SC (HbSC) disease are unknown. A recent adult HbSC disease pilot trial with HU therapy documented a modest laboratory benefit. Our goal was to evaluate the laboratory and clinical responses of selected pediatric patients with severe HbSC disease to HU therapy. PATIENTS AND METHODS: As part of a retrospective case series, patients were selected from the Duke Pediatric Sickle Cell Program based on the frequency and severity of their vasoocclusive events or an episode of acute chest syndrome. Oral HU therapy was started as a single daily dose and increased to the maximally tolerated dose based on myelosuppression. Laboratory evaluation was performed at baseline and monthly thereafter. Once the maximum tolerated dose was reached, laboratory data were monitored bimonthly. RESULTS: We treated six severely affected pediatric HbSC patients with HU for a median of 27 months. Mean corpuscular volume increased significantly (+26 fL) without change in hemoglobin concentration (-0.1 g/dL); neutrophils decreased significantly. Percentage of fetal hemoglobin (+8.5%) and percentage of F cells (+35.7%) increased significantly. Two experienced only mild and reversible toxicity. CONCLUSION: The laboratory responses in our pediatric patients with HbSC disease were striking, with increases in percentage of fetal hemoglobin and percentage of F-cells approaching responses observed in adult and pediatric patients with HbSS disease. All patients improved clinically. Our findings demonstrate that HU therapy benefits pediatric patients with severe HbSC disease, although larger clinical trials of HU therapy in HbSC disease are warranted.


Subject(s)
Antisickling Agents/therapeutic use , Hemoglobin SC Disease/drug therapy , Hydroxyurea/therapeutic use , Acute Disease , Adolescent , Antisickling Agents/adverse effects , Arterial Occlusive Diseases/etiology , Arterial Occlusive Diseases/prevention & control , Chest Pain/etiology , Chest Pain/prevention & control , Child , Dyspnea/etiology , Dyspnea/prevention & control , Female , Hemoglobin SC Disease/blood , Hemoglobin SC Disease/complications , Hospitalization/statistics & numerical data , Humans , Hydroxyurea/adverse effects , Male , Neutropenia/chemically induced , Retrospective Studies , Severity of Illness Index , Syndrome , Thrombocytopenia/chemically induced , Treatment Outcome
9.
Blood ; 98(1): 125-9, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11418471

ABSTRACT

Variants of factor XI containing Gln226 to Arg (Q226 to R) and Ser248 to Asn (S248 to N) substitutions were first identified in an African American family with a history of excessive bleeding. The substitutions have recently been identified in unrelated individuals, suggesting they are relatively common. Both amino acids are located in the third apple domain of factor XI, an area implicated in binding interactions with factor IX and activated platelets. Recombinant factor XI-R226 and factor XI-N248 were compared with wild-type factor XI in assays for factor IX activation or platelet binding. Factor XI-R226 activates factor IX with a Michaelis-Menten constant (K(m)) about 5-fold greater than wild-type protein. The catalytic efficiency of factor IX activation is similar to wild-type protein, however, due to an increase in the turnover number (k(cat)) for the reaction. Iodinated factor XI-N248 binds to activated platelets with a dissociation constant (K(d)) more than 5-fold higher than wild-type protein (55 nM and 10 nM, respectively). Activation of factor XI-N248 by thrombin in the presence of activated platelets is slower and does not progress to the same extent as activation of the wild-type protein under similar conditions. Factor XI-N248 activates factor IX normally in a purified protein system and has relatively normal activity in activated partial thromboplastin time (aPTT) assays. Factor XI-N248 is the first factor XI variant described with a clear functional difference compared with wild-type protein. Importantly, the defect in platelet binding would not be detected by routine clinical evaluation with an aPTT assay.


Subject(s)
Blood Platelets/metabolism , Factor XI/genetics , Factor XI/metabolism , Amino Acid Substitution , Cells, Cultured , Chromogenic Compounds , Factor IX/metabolism , Factor XI/drug effects , Factor XI Deficiency/etiology , Factor XI Deficiency/genetics , Fibroblasts , Humans , Kinetics , Protein Binding , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Thrombin/pharmacology
10.
Blood ; 97(10): 3004-10, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11342424

ABSTRACT

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder characterized by complement-mediated hemolysis due to deficiencies of glycosylphosphatidylinositol-anchored proteins (GPI-APs) in subpopulations of blood cells. Acquired mutations in the X-linked phosphatidylinositol glycan-class A (PIG-A) gene appear to be the characteristic and pathogenetic cause of PNH. To develop a gene therapy approach for PNH, a retroviral vector construct, termed MPIN, was made containing the PIG-A complementary DNA along with an internal ribosome entry site and the nerve growth factor receptor (NGFR) as a selectable marker. MPIN transduction led to efficient and stable PIG-A and NGFR gene expression in a PIG-A-deficient B-cell line (JY5), a PIG-A-deficient K562 cell line, an Epstein-Barr virus-transformed B-cell line (TK-14(-)) established from a patient with PNH, as well as peripheral blood (PB) mononuclear cells from a patient with PNH. PIG-A expression in these cell lines stably restored GPI-AP expression. MPIN was transduced into bone marrow mononuclear cells from a patient with PNH, and myeloid/erythroid colonies and erythroid cells were derived. These transduced erythroid cells restored surface expression of GPI-APs and resistance to hemolysis. These results indicate that MPIN is capable of efficient and stable functional restoration of GPI-APs in a variety of PIG-A-deficient hematopoietic cell types. Furthermore, MPIN also transduced into PB CD34(+) cells from a normal donor, indicating that MPIN can transduce primitive human progenitors. These findings set the stage for determining whether MPIN can restore PIG-A function in multipotential stem cells, thereby providing a potential new therapeutic option in PNH.


Subject(s)
Glycosylphosphatidylinositols/genetics , Hemoglobinuria, Paroxysmal/genetics , Membrane Proteins/genetics , Retroviridae/genetics , Transfection , 3T3 Cells , Animals , B-Lymphocytes/metabolism , Bone Marrow Cells/metabolism , Cell Line , Cell Line, Transformed , Gene Expression , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Hemoglobinuria, Paroxysmal/blood , Hemoglobinuria, Paroxysmal/metabolism , Hemolysis , Herpesvirus 4, Human , Membrane Proteins/deficiency , Membrane Proteins/physiology , Mice , Mutation , Nerve Growth Factor/analysis , Nerve Growth Factor/genetics , Phenotype
11.
Int J Radiat Oncol Biol Phys ; 50(2): 287-93, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11380213

ABSTRACT

PURPOSE: Most radical radiotherapy (RT) candidates with non-small-cell lung cancer (NSCLC) have Stage III disease and ultimately die with distant metastases. We tested the hypothesis that positron emission tomography (PET) using 18-F fluorodeoxyglucose (FDG) would detect more unsuspected metastases in apparent Stage III disease than in Stages I-II. METHODS AND MATERIALS: Staging FDG-PET was performed for 167 NSCLC patients, with Stage I-III by conventional workup, who were candidates for curative therapy with surgery (n = 8), radical chemo/RT or RT (n = 156), or preoperative chemo/RT (n = 3). Each patient was allocated a conventional "pre-PET stage" and a "post-PET stage" that relied on PET when discordance with conventional staging occurred. RESULTS: Stage distribution pre-PET was n = 39 (Stage I), n = 28 (Stage II), and n = 100 (Stage III). In 32 patients (19%), PET detected distant metastasis, most commonly abdominal with 17 cases (adrenal, n = 7; liver, n = 4; other, n = 6). Other sites included lung (n = 10) and bone (n = 6). PET-detected metastasis increased with increasing pre-PET stage from I (7.5%) through II (18%) to III (24%, p = 0.016), and, in particular, was significantly higher in Stage III (p = 0.039). Biopsy confirmation was not routine, but progression occurred at PET-detected metastatic sites or other metastatic sites in all but 3 of the 32 patients by last review. CONCLUSION: PET staging is recommended for radical RT candidates with NSCLC. The highest yield of unexpected distant metastases is observed in Stage III.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/radiotherapy , Female , Fluorodeoxyglucose F18 , Follow-Up Studies , Humans , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Prospective Studies , Radiopharmaceuticals , Tomography, Emission-Computed
12.
J Am Acad Dermatol ; 44(5): 859-61, 2001 May.
Article in English | MEDLINE | ID: mdl-11312437

ABSTRACT

Skin and nail changes from long-term hydroxyurea therapy are reported in adults. Skin and nail changes, including nail hyperpigmentation, longitudinal bands, and hyperpigmentation of the palms and other skin surfaces, developed in 7 children with sickle cell anemia after 6 to 16 weeks of hydroxyurea therapy. Cutaneous and nail changes may occur in children receiving hydroxyurea.


Subject(s)
Anemia, Sickle Cell/drug therapy , Antisickling Agents/adverse effects , Hydroxyurea/adverse effects , Hyperpigmentation/etiology , Nail Diseases/etiology , Skin Diseases/etiology , Adolescent , Child , Female , Humans , Hyperpigmentation/pathology , Male , Nail Diseases/pathology
13.
Genet Med ; 3(2): 132-8, 2001.
Article in English | MEDLINE | ID: mdl-11286229

ABSTRACT

PURPOSE: Infantile glycogen storage disease type II (GSD-II) is a fatal genetic muscle disorder caused by deficiency of acid alpha-glucosidase (GAA). The purpose of this study was to investigate the safety and efficacy of recombinant human GAA (rhGAA) enzyme therapy for this fatal disorder. METHODS: The study was designed as a phase I/II, open-label, single-dose study of rhGAA infused intravenously twice weekly in three infants with infantile GSD-II. rhGAA used in this study was purified from genetically engineered Chinese hamster ovary (CHO) cells overproducing GAA. Adverse effects and efficacy of rhGAA upon cardiac, pulmonary, neurologic, and motor functions were evaluated during 1 year of the trial period. The primary end point assessed was heart failure-free survival at 1 year of age. This was based on historical control data that virtually all patients died of cardiac failure by 1 year of age. RESULTS: The results of more than 250 infusions showed that rhGAA was generally well tolerated. Steady decreases in heart size and maintenance of normal cardiac function for more than 1 year were observed in all three infants. These infants have well passed the critical age of 1 year (currently 16, 18, and 22 months old) and continue to have normal cardiac function. Improvements of skeletal muscle functions were also noted; one patient showed marked improvement and currently has normal muscle tone and strength as well as normal neurologic and Denver developmental evaluations. Muscle biopsies confirmed that dramatic reductions in glycogen accumulation had occurred after rhGAA treatment in this patient. CONCLUSIONS: This phase I/II first study of recombinant human GAA derived from CHO cells showed that rhGAA is capable of improving cardiac and skeletal muscle functions in infantile GSD-II patients. Further study will be needed to assess the overall potential of this therapy.


Subject(s)
Glycogen Storage Disease Type II/therapy , Recombinant Proteins/therapeutic use , alpha-Glucosidases/therapeutic use , Age Factors , Animals , Blotting, Western , CHO Cells , Cricetinae , Enzyme-Linked Immunosorbent Assay , Glycogen/metabolism , Heart/physiology , Heart Diseases/genetics , Heart Diseases/prevention & control , Humans , Infant , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiology , Muscles/pathology , Myocardium/metabolism , Phenotype , Radiography, Thoracic , Time Factors , X-Rays
14.
Am J Hematol ; 67(1): 27-33, 2001 May.
Article in English | MEDLINE | ID: mdl-11279654

ABSTRACT

The acute platelet response to Intravenous Gammaglobulin (IVIG) has been reported to predict response to subsequent splenectomy of patients with ITP. The current study was undertaken to determine if the platelet response to IV anti-D (Winrho-SDF) predicts response to subsequent splenectomy. The 61 HIV-uninfected children and adults in this study had taken part in the pre-licensing studies of IV anti-D and were all those who not only had evaluable platelet responses to IV anti-D but also had undergone splenectomy and had information available describing its 1-year outcome. Results of treatment with IVIG were available in 38 of these 61 patients. Neither response to the initial infusion of IV anti-D, nor response to the initial or last IVIG, predicted the response in either children or adults to subsequent splenectomy. However, response to the last anti-D infusion in adults was strongly correlated (P = 0.003) to response to subsequent splenectomy as was hemolysis >/=2.0 gm/dl after IV anti-D (P = 0.03). There was no overall relationship between response to IV anti-D or IVIG, and response to subsequent splenectomy. However, a good platelet response in adults to the last IV anti-D and a hemoglobin decrease >/=2.0 gm/dl both appeared to predict response to subsequent splenectomy.


Subject(s)
Blood Platelets/drug effects , Immunoglobulins, Intravenous/administration & dosage , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Splenectomy , Adolescent , Adult , Aged , Blood Platelets/cytology , Child , Child, Preschool , Contraindications , Follow-Up Studies , Humans , Infant , Middle Aged , Platelet Count , Prognosis , Purpura, Thrombocytopenic, Idiopathic/surgery , Rho(D) Immune Globulin/administration & dosage , Treatment Outcome , gamma-Globulins/administration & dosage
15.
J Pediatr Psychol ; 26(3): 163-73, 2001.
Article in English | MEDLINE | ID: mdl-11259518

ABSTRACT

OBJECTIVE: To examine the 1-month effects of a pain coping skills intervention in children with sickle cell disease (SCD). METHODS: Forty-six African American children (8-17 years old) were randomly assigned to either a coping skills condition or a standard care control condition. Children were asked to practice daily with audiotaped instructions of skills (e.g., relaxation, imagery). RESULTS: Multivariate analyses of summary measures indicated that children in the coping intervention (versus control group) reported a significantly more active approach to managing pain. Multilevel random effects models applied to daily diary data indicated that on pain days when children practiced their strategies, they had fewer health care contacts, fewer school absences, and less interference with household activities than on days when they did not practice. CONCLUSIONS: Brief training in coping skills followed by minimal therapist contact may lead to a range of benefits when children practice with their skills on a consistent basis.


Subject(s)
Adaptation, Psychological , Anemia, Sickle Cell/psychology , Anemia, Sickle Cell/therapy , Pain/psychology , Adolescent , Anemia, Sickle Cell/complications , Child , Female , Humans , Male , Medical Records , Multivariate Analysis , North Carolina , Pain/etiology , Treatment Outcome
16.
J Rheumatol ; 28(2): 370-2, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11246680

ABSTRACT

Thrombophilia can result from either inherited or acquired conditions. We describe a teenager who developed extensive thrombosis requiring aggressive and prolonged anticoagulation. Laboratory evaluation revealed an acquired lupus anticoagulant, consistent with the antiphospholipid antibody syndrome (APS). DNA analysis revealed inherited thrombophilic mutations in the factor V and methylene tetrahydrofolate reductase genes. We believe that the combination of inherited and acquired hypercoagulable conditions affected her therapeutic response to anticoagulant therapy. Inherited thrombophilic DNA mutations may contribute to the hypercoagulability observed in patients with acquired thrombophilic conditions such as APS and systemic lupus erythematosus.


Subject(s)
Antiphospholipid Syndrome/genetics , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/genetics , Thrombophilia/genetics , Adolescent , Anticoagulants/administration & dosage , DNA Mutational Analysis , Female , Heparin/administration & dosage , Humans , Lupus Coagulation Inhibitor/drug effects , Lupus Coagulation Inhibitor/genetics , Mutation/genetics , Thrombophilia/drug therapy , Venous Thrombosis/drug therapy , Venous Thrombosis/genetics , Venous Thrombosis/physiopathology
17.
J Pediatr Hematol Oncol ; 23(1): 67-8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11196276

ABSTRACT

Hemoglobin D-Iran (Hb D-Iran, beta 22 Glu-->Gln) is a beta-chain variant that was first described in 1973. Hb D-Iran in combination with normal Hb A (Hb D-Iran trait) is a benign condition. Hb D-Iran has also been described in combination with sickle hemoglobin and beta thalassemia, but never as a homozygous mutation. The authors describe a case of homozygous Hb D-Iran in an infant of Pakistani descent. The hematologic values, hemoglobin electrophoresis, peripheral blood smear, and clinical course to date suggest that homozygous Hb D-Iran is a relatively benign condition with mild microcytic anemia, poikilocytosis, and minimal hemolysis.


Subject(s)
Hemoglobins, Abnormal/genetics , Anemia/blood , Anemia/genetics , Erythrocytes, Abnormal , Fetal Hemoglobin/analysis , Hemoglobins, Abnormal/analysis , Hemolysis , Homozygote , Humans , Infant , Male , North Carolina , Pakistan/ethnology
18.
J Clin Oncol ; 19(1): 111-8, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11134203

ABSTRACT

PURPOSE: To prospectively study the impact of (18)F fluorodeoxyglucose (FDG) positron emission tomography (PET) on clinical management of patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: One hundred five consecutive patients with NSCLC undergoing (18)F FDG PET were analyzed. Before PET, referring physicians recorded scan indication, conventional clinical stage, and proposed treatment plan. PET scan results were reported in conjunction with available clinical and imaging data, including results of computed tomography (CT). Subsequent management and appropriateness of PET-induced changes were assessed by follow-up for at least 6 months or until the patient's death. RESULTS: Indications for PET were primary staging (n = 59), restaging (n = 34), and suspected malignancy subsequently proven to be NSCLC (n = 12). In 27 (26%) of 105 of cases, PET results led to a change from curative to palliative therapy by upstaging disease extent. Validity of the PET result was established in all but one case. PET appropriately downstaged 10 of 16 patients initially planned for palliative therapy, allowing either potentially curative treatment (four patients) or no treatment (six patients). PET influenced the radiation delivery in 22 (65%) of 34 patients who subsequently received radical radiotherapy. Twelve patients considered probably inoperable on conventional imaging studies were downstaged by PET and underwent potentially curative surgery. PET missed only one primary tumor (5-mm scar carcinoma). CT and PET understaged three of 20 surgical patients (two with N1 lesions < 5 mm and one with unrecognized atrial involvement), and PET missed one small intrapulmonary metastasis apparent on CT. No pathological N2 disease was missed on PET. CONCLUSION: FDG PET scanning changed or influenced management decisions in 70 patients (67%) with NSCLC. Patients were frequently spared unnecessary treatment, and management was more appropriately targeted.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Neoplasm Staging/methods , Radiopharmaceuticals , Tomography, Emission-Computed/methods , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Patient Care Planning , Prospective Studies , Treatment Outcome , Victoria
19.
J Pediatr Hematol Oncol ; 23(7): 448-51, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11878580

ABSTRACT

PURPOSE: Genetic mutations in the uridine diphosphate (UDP)-glucuronosyltransferase 1A (UGT1A) enzyme promoter have been associated with unconjugated hyperbilirubinemia and Gilbert syndrome. The effects of UGT1A promoter polymorphisms on serum bilirubin levels and symptomatic gallstone formation were studied in a cohort of children with sickle cell anemia (SCA). METHODS: The UGT1A promoter genotype was deterrmined for 115 consecutive children with SCA. Steady-state laboratory parameters and previous cholecystectomy for symptomatic gallstones were recorded retrospectively, then analyzed according to UGT1A genotype. RESULTS: Children with SCA had a lower frequency of the normal (TA)6 UGT1A promoter allele (0.413) than the abnormal (TA)7 allele (0.461). A previously described shorter (TA)5 allele (frequency 0.074) and longer (TA)8 allele (frequency 0.052) were also observed. Children with the 7/7 UGT1A genotype had a significantly higher mean bilirubin level (5.8 +/- 3.1 mg/dL) than those with the 6/6 (2.4 +/- 0.8 mg/dL) or 6/7 genotype (3.0 +/- 1.1 mg/dL; P < 0.001 by analysis of variance). Patients with the 7/7 genotype were more likely to have previous cholecystectomy (87.5%) than those with the 6/6 (35.7%) or the 6/7 genotype (36.1%; P = 0.002 by chi2). CONCLUSIONS: Genetic variation in the UGT1A promoter significantly influences serum bilirubin levels and the development of symptomatic cholelithiasis in children with SCA. The UGT1A promoter polymorphisms represent an important nonglobin genetic modifier of clinical disease expression in SCA.


Subject(s)
Anemia, Sickle Cell/complications , Bilirubin/blood , Cholelithiasis/etiology , Glucuronosyltransferase/genetics , Polymorphism, Genetic/genetics , Promoter Regions, Genetic/genetics , Adolescent , Adult , Child , Child, Preschool , Cholelithiasis/blood , Cholelithiasis/diagnosis , DNA Primers/chemistry , Genotype , Heterozygote , Homozygote , Humans , Polymerase Chain Reaction , Retrospective Studies
20.
Hematology ; 6(5): 347-53, 2001.
Article in English | MEDLINE | ID: mdl-27405530

ABSTRACT

Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, ß-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetra-hydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.

SELECTION OF CITATIONS
SEARCH DETAIL
...